Search Results

Displaying Results 1-25 of 25 "'RDHL'"

Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

RALEIGH, N.C. and TEL AVIV, Israel, Sept. 1, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization

Search Results

Displaying Results 1-25 of 25 "'RDHL'"

Sep 01, 2026, 07:00 ET RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Aug 31, 2026, 07:00 ET RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Aug 31, 2026, 07:00 ET RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Jul 28, 2026, 07:00 ET Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

Jun 22, 2026, 16:10 ET RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

Jun 18, 2026, 08:00 ET RedHill Biopharma Announces Up To $19.4 Million Private Placement

Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

Jun 08, 2026, 07:00 ET RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

Jun 03, 2026, 12:04 ET RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

Jun 02, 2026, 08:00 ET RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

Apr 30, 2026, 07:00 ET RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

Mar 04, 2026, 17:46 ET H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences

Jan 05, 2026, 07:00 ET RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Dec 01, 2025, 07:00 ET RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Nov 04, 2025, 12:01 ET RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Oct 22, 2025, 16:50 ET RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 20, 2025, 09:05 ET CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 09:00 ET RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Sep 29, 2025, 07:00 ET RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo